Sally Dy

Sally Dy is a medical professional with extensive experience in medical leadership roles within the pharmaceutical industry. From April 2019 to July 2022, Sally served as Medical Director at Alexion Pharmaceuticals, responsible for medical monitoring and protocol development for Phase 3 studies in neurology, and later as Medical Director for Clinical Development Sciences focusing on complement inhibitors for rare diseases. Prior to Alexion, Sally held the position of Medical Director for Combination Products at Takeda, providing expertise in rare diseases and gastrointestinal and neuroscience areas. Most recently, from August 2022 to April 2023, Sally worked as Senior Medical Development Director at Ipsen, focusing on metabolism and R&D. In May and June 2023, Sally took a career break to pursue personal goals. Educationally, Sally earned an MD from the University of Santo Tomas College of Medicine and Surgery and a BS in Biology from the University of Santo Tomas.